Pathophysiology of renal tubular obstruction: Therapeutic role of synthetic RGD peptides in acute renal failure  by Noiri, Eisei et al.
Kidney International, Vol. 48 (1995), pp. 1375—1385
PERSPECTIVES IN CLINICAL NEPHROLOGY
Pathophysiology of renal tubular obstruction: Therapeutic role of
synthetic RGD peptides in acute renal failure
In his famous work On the Natural Faculties, Galen of Perga-
mum introduced the idea of "attraction" [6AKi] as the principal
mode of kidney function: the attraction of blood to the kidney, he
claimed, results in the production of urine [1]. Though unproven
in Galen's ancient times and entirely rejected by the later gener-
ations as a mechanistic explanation of renal function, the concept
of attraction has not only survived, albeit in a modified form, but
has become one of the cornerstone principles of modern physiol-
ogy and our current understanding of the pathophysiology of
processes as diverse as platelet aggregation, metastases, immune
recognition and wound healing, to name a few, all of which are
governed by adhesion molecules. Here we review the role of
adhesion molecules in the pathophysiology of tubular obstruction,
focusing on the integrins and their newly recognized function in it.
The importance of renal tubular obstruction in the pathogene-
sis of acute renal failure (ARF) was brought to center stage by a
series of elegant microdissection studies by Oliver, MacDowel!
and Tracy [2]. Using servo-null pressure monitoring of the
proximal tubular pressure in diverse models of ARF, investigators
have provided solid evidence for the elevation in hydrostatic
intratubular pressure concomitant with the unchanged stop-flow
and estimated glomerular capillary pressures, further confirming
the tubulo-obstructive component of this syndrome [3—5]. It has
been concluded, therefore, that tubular obstruction and elevated
proximal tubular pressure equilibrate glomerular filtration pres-
sure, thus leading to the persisting oliguria. Necrotic epithelial
cells have been postulated to provide the matrix for casts obstruct-
ing the tubular lumen. Recent findings of viable epithelial cells in
the urine of patients and experimental animals with ARF, how-
ever, cast doubt on the postulated schema and suggest the
possibility of epithelial cell detachment as an important contrib-
utor to the development of tubular obstruction [6—8].
In the following discussion we develop this theme, providing
data on the possible mechanism(s) of tubular obstruction in
ischemic ARF, and on the therapeutic strategies in and benefits of
inhibiting tubular obstruction, and suggest some future directions
of this fledgling field of investigations.
Integrins: Biochemistry, function, and distribution
Adhesion molecules mediating cell-matrix and cell-cell attach-
ment belong to five families: Ig-like molecules (ICAMs, VCAM-1
and PECAM-1), selectins (L-, P- and E-selectin), carbohydrate
ligands for selectins (sialyl Lewisx and G1yCAM-1), cadherins
(uvomorulin, or E-CAM, L-, K- and N-CAMs) and integrins.
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Integrins are noncovalently-bound heterodimeric glycoproteins
composed of a and /3 subunits. To date, 16 distinct a subunits and
8 13 subunits have been identified on the protein level [9].
Members of this large family of receptors share several common
features. Both subunits have a single hydrophobic transmembrane
domain, relatively short cytoplasmic tails and massive extracellu-
tar domains. The latter domains are compactly folded by virtue of
disulfide bonding, associated together, and both contribute to the
formation of the ligand-binding domain. All a subunits contain a
sevenfold repeat of a homologous segment, the last three or four
repeats of which are likely to contribute to divalent cations
binding. The 13 subunits contain a fourfold cysteine-rich repeat
responsible for the folding via internal disulfide groups. Some a
subunits, such as the a1 and a2, contain a 180 amino acid segment,
termed the I domain which, probably imparts some specificity to
the receptors. Cytoplasmic domains of the /3 subunits are indis-
pensable to connecting the receptors to the cytoskeleton. Cyto-
plasmic tails of /3 subunits directly bind to talin and a-actinin; the
latter can bind directly to actin, thus forming a one-protein link
between integrins and cytoskeleton [10].
Integrin receptors are regulated at several levels. The long-term
regulation is accomplished through their expression on the cell
surface, while the rapid regulation of integrin affinities and
specificities is modulated by various extracellular and intracellular
signals. These processes are comprehensively discussed in several
excellent reviews [11—15], which focus on the role of divalent
cations, inside-out and outside-in signaling, and the extracellular
matrix in producing conformational changes of the receptor and
modulating its function from the inactive to the activated state.
Integrins are abundantly expressed in renal tubules. Immuno-
histochemical localization of different subunits has revealed that
proximal tubules express subunits a6, a1 and a3, that distal tubules
express subunits a1, a2, a3 and a6, and that the /31 subunits are
present along the entire tubule [16—18]. Variations in fixation
procedures may have accounted for some of the contentious
results regarding the distribution of the a1 and a3 subunits along
the nephron. Clearly, in situ hybridization approach is needed to
resolve the existing differences and to gain further insight into the
integrins expressed along the nephron.
The above findings on the distribution of integrin receptor
subunits along the nephron permit us to make conjectural con-
clusion as to the nature of heterodimers present. It appears that
the proximal tubule expresses a1131, a3/31 and a6/31 (the possibility
of ag34 expression is less likely, because the /34 subunit was
undetectable in the human kidney [19]). The distal tubule is likely
to express, in addition to the above receptors, a2f31 heterodimer.
The binding specificities of individual receptors formally en-
countered in renal tubules are presented below [11—14]. It should
be stressed, however, that the specificities currently assigned to
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these receptors for the particular matrix proteins may be incom-
plete. There is compelling evidence that structurally and function-
ally different isoforms of laminin, collagen and fibronectin exist
and that these isoforms are expressed in an organ- and site-
specific manner, including various segments of the nephron [20,
21].
a1f31 and a2/31
These heterodimers are receptors for collagen (types I and IV)
and for laminin. The a21 receptor can also bind to tenascin and,
perhaps, to fibronectin. The binding sites for these receptors on
collagen type IV are as yet unknown. The a2f31 receptor binds to
the collagen type I (possibly the Asp-Gly-Glu-Ala sequence),
whereas the respective binding site for the c1j31 receptor remains
unknown. It is not clear whether these receptors recognize RGD
(Arg-Gly-Asp) ligands or other related sequences containing
aspartic acid residue, such as LDV (Leu-Asp-Val) or DGEA
(Asp-Gly-Glu-Ala), on collagen or other adhesion substrates.
a3f37
This is a multifunctional receptor for laminin, collagens type I
and IV, fibronectin, and epiligrin. The receptor recognizes the
RGD (Arg-Gly-Asp) sequence on fibronectin, but probably not
on other matrix proteins [22]. When the major fibronectin recep-
tor, a5131, is present the a3131 binds poorly to fibronectin, whereas
cells readily attach to fibronectin via this receptor in the absence
of aj31. This adhesion is highly enhanced in the presence of Mg2
and Mn2, The receptor localizes, depending on the conditions of
cell culture, either at focal contacts, where it serves as a cell
anchor to substratum, or at cell-cell contacts, where it promotes
cell aggregation [231. Additional data on cell-matrix and cell-cell
adhesion via this multifunctional receptor are presented below.
This is a receptor (activation-dependent in hemapoietic cells)
for the E8 fragment of laminin, existing in two isoforms, a6A and
n6, that differ in their cytoplasmic domains. Both receptors
interact with laminin isoforms, kalinin and merosin [241.
aj33
This RGD-recognizing vitronectin receptor has affinity to sev-
eral other ligands including thrombospondin, von Willebrand
factor, fibronectin, and fibrinogen, all of which are important in
endothelial cell adhesion, spreading, and migration. Preliminaiy
observations [25] indicate that this integrin is weakly expressed in
tubular epithelial cells of human kidneys, and the expression is
enhanced in renal tumors. The functional role of the a,/33 integrin
receptor in epithelial cells remains unknown.
Redistribution of integrins in stressed epithelial cells
Our previous study of BSC-1 cells subjected to oxidant stress
[26] yielded an intriguing observation on the loss of the normal
highly polarized distribution of several integrin receptor subunits.
Using confocal microscopy, we observed that cells growing as a
monolayer exhibited integrins predominantly at the basolateral
membranes. This normal pattern underwent a rapid transforma-
tion (within 10 to 20 mm) from a highly polarized basolateral
expression to an ostensibly random distribution between the
apical and basolateral membranes upon application of oxidant
stress (Fig. 1). Similar observations were made by Lieberthal et al
(personal communication) in renal tubular epithelial cells exposed
to chemical anoxia. Based on the above findings, we propose a
more generalized picture of integrin distribution in stressed
epithelial cells (Fig. 2). This view is further buttressed by a series
of observations obtained in our laboratory and by other investi-
gators (see below). The cornerstone of the proposed hypothesis is
that diverse stress situations result in a loss of the normal polar
distribution of integrins. To fully appreciate the mechanisms and
the consequences of such a phenomenon, this problem must be
considered in detail.
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Fig. 1. Confocal fluorescence microscopy images
of the distribution of the n subunit of integrins in
BSC-1 cells: A - intact, B - exposed to oxidant
stress.
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Cytoskeleton
Integrins
Epithelial cell polarity is one of the major attributes of this
cellular barrier between the external and internal milieu. The best
studied precedent in epithelial cells is related to the stress-
induced loss of the polar distribution of Na/K-ATPase [27].
Other membrane proteins can undergo repolarization or depolar-
ization upon imposition of stress. Integrins in keratinocytes or
corneal epithelial cells undergo a series of transformations during
the processes of both maturation and wound healing, respectively
[28, 29]. The plasticity of the integrins' repertoire and distribution
is also exemplified by the malignant transformation of epithelia
and the associated changes in the expression of integrins [30, 31].
One of the most striking transformations has been observed in the
basal cells of prostate. Normally these cells express a6, and /34
integrin subunits, with the /3 integrin receptors localized to the
basolateral surface of basal cells. In prostate carcinoma, the 134
integrin subunits are completely lost, while the aj31 integrins are
found in a diffuse pattern on the plasma membrane of basal cells
[32]. Hence, the phenomenon of redistribution of the normally
polarized integrins occurs under many different circumstances and
serve various physiological functions. The mechanisms governing
this stress response in renal tubular epithelial cells are, probably,
diverse.
Cytoskeletal disruption
Microfilament disruption in proximal tubular cells represents
an early event in the pathophysiology of ischemic and nephrotoxic
ARF [33, 34]. In their functional mode, integrins constitute a
membrane-spanning component in a chain of proteins which
binds to particular sites of matrix constituents recognized by
individual receptors, and via a group of intermediaries (that is,
vinculin, talin and a-actinin) is tethered to the filamentous actin
[35]. The entire cascade can be disrupted by interference at any
point of connection. By microinjecting the 27-kD proteolytic
fragments of a-actinin (these fragments contain the binding site
for actin) or the 53-kD fragments (these fragments contain the
binding site for the f3 subunit of integrins) into fibroblastic cells
REF 52, BSC-1 and MDCK cells, Pavalko and Burridge [36]
observed disassembly of stress fibers at 30 to 60 minutes postin-
Fig. 2. Working hypothesis of causes and
consequences of the redistribution of integrin
receptors from their predominantly basolateral
location to the apical cell membrane. Left panel.
An epithelial cell with the polarized expression
of integrins and their functional coupling to the
matrix and to the cytoskeleton. Exposure to
oxidant stress or to chemical anoxia result in
the redistribution of integrins, as shown in the
central panel. Potential causative factors for the
loss of integrin polarity are shown in boxes.
Right panel. Cartoon of the consequences of
this event: cell dislodgement and cell-cell
interactions. Here, for simplicity of depicting a
heterophilic type of interaction, a different class
of integrins is shown with triangles.
Abbreviations are: PKs, protein kinases; TS,
thrombospondin; TN, tenascin; SPARC,
secreted protein acidic and rich in cysteine.
jection, while the focal adhesions remained preserved. By two
hours post-injection, only a few focal adhesions were detectable.
Similarly, disruption of F-actin with cytochalasin leads to the
collapse of focal adhesions [37]. In this vein, stress-induced
depolymerization of F-actin [33, 38, 39] may well represent an
important mechanism for rapid changes in the binding of integrins
to their ligands in the matrix.
State of phosphotylation
It is quite possible that the degree and the site of phosphory-
lation may regulate the affinity of talin to integrins and integrins to
their ligands, thus eventually modulating cell-matrix attachment.
Turner, Pavalko and Burridge [40] have demonstrated that the
phorbol ester-induced activation of protein kinase C results in a
rapid (within 20 mm) loss of stress fibers and focal adhesions from
BSC-1 cells. These phenomena were accompanied by an increased
level of talin, but not vinculin, phosphorylation. Treatment of
human fibroblasts with interleukin-1/3 was associated with rapid
phosphorylation and redistribution of talin, both peaking at 15 to
30 minutes, and accompanied by disorganization of the cytoskel-
eton [41]. In addition to this observation, there is evidence that
a-actinin and vinculin, both PIP2-binding proteins, are substrates
for the tyrosine-kinase-activated PLC resulting in hydrolysis of
PIP2 with the subsequent reorganization of the cytoskeleton [421.
Phosphorylation of integrin receptors may also modulate their
function. The establishment of focal adhesions via integrin-
extracellular ligand binding initiates a cascade of signaling events
(Fig. 3). It has been demonstrated that the formation of cell-
matrix and cell-cell contacts results in a rapid activation of the
Nat1H exchanger and cell alkalinization [43, 44], elevation of
cytosolic calcium concentration, possibly, due to the activation of
a 50-kDa /33 integrin-associated protein, presumed to represent an
integrin-regulated calcium channel in endothelial cells and neu-
trophils [45, 46], delayed stimulation of a K current [47], and a
series of tyrosine phosphorylation reactions mediated via activa-
tion of focal adhesion kinase [48, 49]. Conversely, the reduction of
cell-substrate adhesion and detachment of cells from their matrix
is associated with the activation of a phosphotyrosine phosphatase
and the decreased tyrosine phosphorylation of focal adhesions
[50]. It has been shown that the phosphorylated form of the
Stress
Homophilic
and heterophilic
interactions
Possible mechanisms of the loss of polarized distribution
of integrins
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Fig. 3. Integrin signaling cascades and interactions with other signaling systems. Interaction of integrin receptors with focal adhesion kinase leading to cell
remodeling and, possibly, to feedback regulation of integrins is depicted with thick arrows. Potential interactions between integrin receptors and various
growth factors (such as epidermal growth factor, FGF, or insulin and insulin receptor substrate-i, IRS-i) are outlined with dots. Actions of serpentine
G-protein-coupled receptors on the elements of integrin signaling are shown on the right (dotted area). See the text for details.
integrin subunit has different subcellular localization than the
nonphosphorylated form, suggesting that tyrosine phosphoryla-
tion is involved in cellular traffic of the receptor [51]. The
observed versatility of signaling mechanisms triggered by the
establishment or dissolution of focal adhesions can provide the
means for the conformational changes of proteins composing the
focal adhesions (such as the 13 integrin, paxillin, and tensin, all
containing phosphotyrosine) and explain the phenomena of affin-
ity modulation of integrins toward the extracellular matrix pro-
teins, outside the cell, and toward the cytoskeletal elements, inside
the cell [521.
The list of the substrates for tyrosine kinase phosphorylation is
continuously growing, and presently includes vinculin, talin, ten-
sin, paxillin, integrins, pp125K, cadherins, and catenins.125F represents so far the best studied tyrosine kinase
associated with focal adhesions. This protein is autophosphory-
lated during cell adhesion (the cytoplasmic domain of /3 subunits
is necessary for this reaction), but it also undergoes autophos-
phorylation in response to pp60vsrc, bradykinin, endothelin, and
sphingosine, resulting in the increase in its tyrosine kinase activity.
Dephosphorylation of ppi25'' may be accomplished in part via
activation of the SH2 domain-containing protein tyrosine phos-
phatase Syp (SHPTP2) which is activated by the insulin receptor
substrate-i (IRS-i). This IRS-i per se can be associated with
integrin receptor a,f33 [53], thus providing the long-sought link
between growth factors and integrins. In Rat-I fibroblasts express-
ing insulin receptor, insulin treatment resulted in dephosphoryla-
tion of pp125' whereas in fibroblasts transfected with insulin
receptor cDNAs lacking the C-terminal twin tyrosine phosphory-
lation sites the degree of pp125K phosphorylation was unaf-
fected by insulin [54]. In turn, Grb2 and P1 [3]-kinase are two
known substrates of ppi25'' [55, 56]. Collectively, these studies
interconnect integrins with receptors for hormones and growth
factors, and implicate the state of ppl25'' phosphorylation in
modulation of the Ras/MAPK and PIP3 signal transduction
pathways.
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Activation of proteases
Components of integrin receptors, together with talin and
a-actinin, are known substrates for proteases. It has been dem-
onstrated that at least one calcium-activated neutral protease,
calpain, co-localizes with the elements of focal adhesions [57].
Cleavage of integrin receptor subunits by calpain, such as the
cytoplasmic domain of the 134 subunit, has previously been docu-
mented [58]. In our experiments, pretreatment of BSC-1 cells with
an inhibitor of calpain, MDL 28170, resulted in a dramatic
decrease in the number of BSC-1 cells detached from the matrix
upon exposure to oxidant stress (unpublished observations). The
potential role of calpain and other proteases deserves further
investigation.
Induction of NO synthase
Increased NO release has been implicated in the pathophysiol-
ogy of ARF [59]. NO synthases, both constitutive and inducible
forms, are expressed in tubular epithelial cells and in several cell
lines derived from renal tubular epithelia [60, 61]. As a powerful
oxidant, NO can affect adhesion of epithelial cells to their
matrices [62]. Our laboratory has observed that, in BSC-1 cells
exposed to oxidant stress, pretreatment with antisense oligode-
oxynucleotides directed to the initiation codon of the inducible
NO synthase partially prevented cell detachment and attenuated
cell death (Peresleni et al, unpublished observations).
Modification or conformation of matrix proteins
Changes in availability and composition of ECM are the known
modulator of integrins' affinity [63]. Different stress situations
have been reported to alter matrix proteins. Hydroxyl radicals
damage fibronectin by causing the loss of tiyptophane, the
increase in bityrosine and extensive crosslinking [64]. These
changes carry a potential to affect cell-matrix adhesion.
Cell locomotion
Since the classical studies by Abercrombie, Heaysman and
Pegrum [65], the idea of a redistribution and directional move-
ment of membrane proteins during cell locomotion has gained
solid experimental support. Several membrane-spanning proteins
expressed on the basal surface of the cell are retrieved and
re-expressed on the apical surface during cell migration. Since the
integrity of epithelial cell monolayers subjected to stress becomes
impaired and intercellular gaps are formed, the cells migrate
inwardly to the voids and seal them [66]. Using confocal micros-
copy of BSC-1 cells labeled with a biotinylated RGD peptide, we
observed that the binding sites, ordinarily expressed on the basal
membrane, were expressed on the apical membrane of the cells
migrating into a wound (MSG, unpublished observations). There-
fore, it is conceivable that the loss of polarity in the expression of
integrins may be due, at least in part, to the process of epithelial
cell migration, and that the locomoting cells, compared to the rest
of the population, are less tightly attached to the matrix and
express integrins on the apical surface more abundantly.
Endogenous antiadhesins and repulsins
There is accruing evidence that many cells synthesize and
secrete substances which, in a paracrine or autocrine fashion,
interfere with cell-matrix adhesion. One of the best studied
secretory products is the extracellular matrix-associated glycopro-
tein SPARC (acronym for "secreted protein acidic and rich in
cystein," also termed osteonectin, BM-40 or 43-kD protein) which
selectively disrupts focal adhesions [67]. This antiadhesin and its
mRNA are expressed in the fetal and adult kidney, and are
induced in stress situations and in tissues undergoing remodeling
and repair. Together with other known antiadhesins, throm-
bospondin and tenascin, SPARC may be a candidate molecule
contributing to the detachment of stressed renal tubular epithelia.
This speculation clearly warrants future testing. Cytotactin is an
example of a growing family of repulsins. This molecule functions
amphitropically, as it can mediate cell adhesion, but can also
discourage cells from attachment and spreading [reviewed in 68].
The role of these molecules as candidates for modulation of renal
tubular epithelial cells adhesion calls for investigation.
The functional consequences of the loss of polarized distribu-
tion of integrins in renal tubular epithelial cells may be twofold.
First, cell detachment from the matrix is a well-established
consequence of the dysfunction of several integrins. Carter et al
[69] have demonstrated that anti-a3f31 monoclonal antibody P1B5
detached human keratinocytes, which express this receptor, from
their laminin- or fibronectin-containing substratum, Similar de-
tachment is observed in BSC-1 cells exposed to this antibody or to
the cyclic RGD peptide, 10 to 50 LM (MSG, personal observa-
tion). There is emerging evidence that disruption of epithelial
cell-matrix interactions leading to the detachment of these an-
chorage-dependent cells, or anoikis (Greek for homelessness),
induces programmed cell death [70—72]. Hence, renal tubular cell
detachment from the matrix is a likely consequence of integrin
redistribution from the basal cell surface. Second, the redistribu-
tion of integrins from the basal to the apical cell membrane
predisposes in situ cells to promiscuous interactions with the
dislodged cells or with matrix fragments, as the evidence pre-
sented below demonstrates.
Model of tubular obstruction: Cell-cell and
cell-matrix-cell adhesion
The fate of the dislodged tubular epithelial cells must now be
addressed. As Racusen et al [6] and Graber et al [7] have pointed
out, viable cells can be harvested from the urine of patients with
ARF. On the other hand, based on microdissection studies by
Oliver et al [2], it is known that a proportion of tubules shows
partial or complete obstruction. It is, therefore, reasonable to
assume that some of these dislodged tubular epithelial cells
become aggregated to form tubular casts. The real question is,
How does this occur?
We have considered the possibility that integrins expressed on
the apical surface of tubular epithelia can promote cell-cell
adhesion when presented with a dislodged cell. The major pre-
requisite for such a mechanism to take place is the functional
competence of the apically expressed integrins. Indeed, using
cell-cell adhesion assays, together with the measurements of
matrix-coated latex beads' attachment to the stressed BSC-1 cells,
we have demonstrated a significant increase in cell-cell and
cell-bead attachment to monolayers which lost their polar distri-
bution of integrins [73]. Hence, the ability of apical integrins to
mediate adhesion should not be the limiting factor in cellular
aggregation.
The possible cellular interactions — homophilic and hetero-
philic, as well as via fragments of matrix proteins — are cartooned
1380 Noi,iet a!: Renal tubular obstruction
in Figure 2. The very fact that this process is inhibited, at least in
part, by RGD peptides ([73] and see below) narrows the number
of participating molecular candidates. In accord with our previous
observation on the expression of the a3f31 multifunctional recep-
tor on the apical surface of stressed BSC-1 cells [26], the
possibility of homophilic interactions via this receptor should be
considered. In human keratinocytes, cell-cell adhesion was inhib-
ited by the P1B5 antibody against the a3 subunit or with the
monoclonal anti-/31 antibody P4C10 [69]. The relocation of the
integrins from focal contacts to cell-cell contacts was documented,
a fact supportive of either type of interaction, homo- or hetero-
philic. By transfecting human a3 cDNA into K562 cells, normally
lacking the endogenous a3, Weitzman et al [74] were able to
demonstrate that the transfectants accomplished adhesion,
spreading, and homophilic cell-cell aggregation via the a3f31
receptors. Homophilic interactions via the a3131 receptor were
further established in studies of MG-63 human osteosarcoma cells
which express this receptor. The immobilized receptor supported
the adhesion of these cells, the process which was inhibited by
monoclonal antibodies against both a3 and f3 subunits [75]. In
addition, only a3 131 integrin from detergent extracts of the cells
specifically binds to the affinity matrix containing the purified a3/31
receptors [75]. Larjava et a! [76] have documented that the aj31,
a3131, and a5 f3 integrins were clustered in areas of cell-cell
contacts. These investigators suggested that in epithelial cells the
above receptors, in addition to their known role in substrate
adhesion, can also function in cell-cell interaction.
Another possible scenario for the RGD-sensitive cell-cell inter-
action is suggested by the recent studies employing the I3-
activating antibody TS2/16 [77]. B lymphocyte cell lines expressing
the a431 integrin, which has no apparent affinity to RGD peptides,
acquired the capacity to recognize the RGD sequence after
stimulation with TS2/16 antibody. This activating antibody also
enhanced attachment of cells transfected with human a3 cDNA,
KA3 cells, to fibronectin [74]. Unfortunately, the effect of RGD
peptides on the attachment of these transfectants has not yet been
examined;
The possibility of interaction between the opposing receptors
via fragments of matrix proteins was considered in the study by
Larjava et al [76]: neither fibronectin, laminin, nor type IV
collagen co-localized to cell-cell contacts. Hence, the existing
precedent in other epithelial cells supports the involvement of
hornophilic and, less likely, heterophilic interactions in renal
tubular cell aggregation. Although a contribution of cadherins to
this cell-cell adhesion is possible, especially in view of the existing
sequence homology between cadherins and integrins [78], this
type of adhesion would be resistant to RGD peptides and,
therefore, is beyond the scope of the present review.
As mentioned above, cell-cell interaction via integrin receptors
can be mediated, at least in part, by the soluble fragments of
matrix present in the urine or, alternatively, through matrix
fragments torn from the basement membrane during the process
of cell detachment. Together with the known components of the
tubular basement membrane, other RGD-containing proteins,
such as osteopontin, Tamm-Horsfall protein, or IGF-binding
protein, may participate in the bridging integrin receptors of
neighboring cells. Finally, the possibility that the dislodged cells
may attach to the denuded basement membrane, in a way similar
to the adhesion of platelets to the sites of endothelial cell damage
and loss, has not been excluded. These possibilities are addressed
below in our discussion of in vivo experiments with two cyclic
RGD peptides characterized by vastly different potency in inhib-
iting cell-matrix adhesion.
The above in vitro data and conclusions have been further
tested by monitoring the proximal tubular pressure in rats with an
ischemic model of ARF. One of us (GFD) has consistently
observed the elevation of proximal tubular pressure in rats after
the release of renal artery occlusion. When a linear RGD peptide
was infused into the renal artery, however, the elevation of
proximal tubular pressure was curtailed, the effect of which was
not reproduced by the inactive peptide or by a vehicle alone [73].
Our recent immunohistochemical studies of ischemic kidneys
(Romanov et al, manuscript in preparation) have shown the
appearance of the immunodetectable I3 subunit, usually localized
to the basal aspect of tubular epithelia, on the luminal surface of
tubular epithelial cells and on the surface of desquamated and
conglomerated cells within tubular lumen. These observations are
consistent with the proposed role of integrins in triggering the
cascade of events leading to cellular detachment and aggregation
of detached cells. It is important to bear in mind that all these
interactions leading to cellular agglomeration were inhibited by
synthetic RGD peptides.
Disintegrins and synthetic cyclic RGD peptides
Disintegrins comprise a large family of proteins containing the
RGD motif or a related sequence with a high affinity to integrin
receptors. Initially, these proteins were purified from snake
venoms. Scarborough et a! have screened sixty-two snake venoms
in search of a potent inhibitor of platelet aggregation [79].
Fifty-two of them inhibited glycoprotein (GP) Jib-lila-mediated
platelet adhesion, but obly one of them, termed barbourin (from
the southeastern US pigmy rattlesnake Sistrurus m. barbouri), was
specific for the GPIIb-IIIa versus other integrins. Surprisingly, this
peptide, despite its high structural similarity to other viper venoms
with disintegrin properties, did not contain the RGD sequence
and instead possessed the sequence Lys-Gly-Asp (KGD).
Chemical synthesis of RGD peptides intends to mimic the
properties of disintegrins. Linear RGD-containing peptides do
not guarantee the necessary structural stability and, thus, are usually
less potent than their venom analogs. In addition, it is known that
linear RGD peptides (such as GRGDS and GRGDNP) are rapidly
excreted and degraded in vivo [80]. Therefore, several strategies such
as polymerization or complexation with macromolecules have been
employed in the past to improve the biological properties of such
peptides. However, these strategies invariably led to the produc-
tion of large molecules Which a priori would not pass the glomer-
ular filtration barrier to reach the tubular lumen. An alternative
strategy of cyclization of RGD peptides has been shown to
provide the necessary structural constraints and, thus, resulted in
a significant increase in their affinity for integrins and inhibitory
potency [80—82] without compromising the filterability of the
peptides.
We have previously characterized two cyclic RGD peptides with
contrasting properties in BSC-l cell-matrix and cell-cell adhesion
[83]. RGDDFV exerted a potent inhibitory effect on BSC-1
cell-matrix adhesion: the IC50 for adhesion to fibronectin and
laminin was 2 tLM and 250 M, respectively. RGDDFLG was less
potent in inhibiting BSC-1 cell adhesion to fibronectin and
laminin: the maximal concentration of peptide used in these
assays resulted in a 58% inhibition of adhesion to fibronectin and
a 69% inhibition of adhesion to laminin. RDADFV, a cyclic
peptide which does not contain the RGD sequence, thus useful as
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Fig. 4. Histologic findings in postischemic kidneys 3 days after ischemia. A and B. Untreated ischemic kidneys. C and D. RGDDFV-treated ischemic
kidneys. Cyclic RGD peptide-treated kidneys show virtually no tubular dilatation and a very mild tubular obstruction, compared with the severely
dilatated and obstructed tubules in the nontreated group. Occasional necrotic and dividing tubular epithelial cells in situ are observed with equal
frequency in both groups. Magnification >< 100 (A and C) and X400 (B and D).
a control, did not affect cell-matrix adhesion. Using PepTite 2000
as adhesion substrate, RGDDFLG (25 /.tM) did not affect BSC-1
cell adhesion, whereas an equimolar concentration of RGDDFV
inhibited 90% adhesion [83].
BSC-1 cells exhibited a strong tendency for self-conglomeration
in suspension: the number of single cells progressively decreased
with time in suspension, while the number of conglomerated cells
progressively increased [83]. When cell-cell adhesion assays were
performed in the presence of the cyclic RGD peptides at a
concentration similar to that used in vivo, the process of cellular
aggregation was virtually abolished. Collectively, these findings
demonstrated that cyclic ROD peptides used in these studies
affected cell-matrix and cell-cell adhesion with different potencies;
although differing in effectiveness in inhibiting cell-matrix adhe-
sion, both peptides were equipotent in the cell-cell adhesion assay.
Based on profound differences in the inhibitory potency of these
peptides, we utilized them for in vivo experiments (see below) at
the concentration (—4 LLM) which proved to be effective for
RGDDFV, but ineffective for RGDDFLG.
Effects of cyclic peptides on the course of ischemic acute
renal failure
The systemic effects of these cyclic peptides were examined in
vivo in a rat model of ischemic ARF [83]. Cyclic RGDDFLG- and
RGDDFV-treated groups showed a significantly lesser retention
of Cr, as well as an accelerated recovery of CCr (P < 0.05) on
postoperative day 1, compared to both control groups (animals
treated with either the inactive cyclic peptide or with the vehicle).
In addition, a significant difference in Cr between cyclic
RGDDFLG- or RGDDFV-treated and cyclic RDADFV-treated
groups was observed on postoperative day 3. These data indicate
that the recovery of renal function after ischemic injury occurred
faster in cyclic RGDDFV-treated (2 days) or RGDDFLG-treated
(3 days) groups, compared to animals treated with either the
inactive peptide or with the vehicle (P < 0.05). The rank order for
the cyclic peptides in ameliorating ischemic ARF and accelerating
recovery of Cr was as follows: cyclic RGDDFV  RGDDFLG
RDADFV.
Microscopic examination of the urinary sediments revealed
striking differences between the experimental and control groups.
While control urine samples showed conglomerates of epithelial
cells on postischemic day 1, the urinary sediments of RGDDFLG-
or RGDDFV-treated animals displayed large numbers of dis-
persed cells.
Histologic examination of rat kidneys obtained from animals
treated with the RGDDFV peptide or with the vehicle revealed
striking differences in the degree of tubular obstruction. Three
days after acute ischemia, treated kidneys showed no tubular
dilatation and a very mild tubular obstruction, compared with the
severely dilatated and obstructed tubules in the nontreated group.
Occasional necrotic and dividing tubular epithelial cells in situ
were observed with equal frequency in both groups (Fig. 4). These
data suggest that cyclic ROD peptides do not significantly affect
the fate of tubular cells in terms of necrosis or mitogenesis, but
acted rather by preventing tubular obstruction. This conclusion is
consistent with the other findings.
The time course of the effect of cyclic peptides was examined in
rats subjected to 45 minutes renal artery occlusion and injected
with the peptide at 2 and eight hours after the reperfusion
commenced. As shown in Figure 5, when ROD peptides were
injected at two hours postischemia, the recovery of creatinine
clearance was accelerated to the same extent as it was with the
peptide injection immediately after the release of a clamp. This
effect, although it persisted in a group of animals that received the
peptide after eight hours, was less pronounced, compared with the
two hour group. It is possible that the adhesive events critical for
the subsequent tubular obstruction occur early after an ischemic
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Fig. 5. Dependence of creatinine clearance on the timing of injection of
cyclic RGD peptide. Measurements were performed 24 hours post-isch-
emia. Symbols are: () immediate injection; (0), (X) injection was made
2 and 8 hours, respectively, after release of renal artery clamp; (•) control
ischemia. P < 0.05 was observed between (0, 0, and X) vs., (•); between(0) and (x), (•).
episode, when they can be prevented by administration of cyclic
RGD peptides.
The observed effects of cyclic RGD peptides were possibly
mediated by their tubular effects. Given that the molecular
weights of these cyclic peptides are less than 900 Da, and their
electrical charge is close to neutral, it is reasonable to assume that
the peptides should readily undergo glomerular filtration [84, 85].
To prove that a systemically injected RGD peptide indeed
appears in the tubular lumen, where it could act on the desqua-
mated cells, we next examined urine sediments obtained from rats
subjected to renal ischemia and administered the biotinylated
RGD peptide, RGD[Bt-K5]. Urinary samples collected at three
hours postoperatively and stained with Rhodamine B streptavidin
revealed the presence of the biotinylated ligand on the surface of
fixed non-permeabilized cells in the urine sediment. These data
are consistent with the appearance of RGD peptides in the
tubular lumen, probably as a result of their glomerular filtration.
The data obtained with radiolabeled peptides confirmed and
further expanded these observations (see below).
These studies demonstrated that a single systemic administra-
tion of cyclic peptides in vivo ameliorated ischemic ARF, proba-
bly, through their inhibitory action on cell-cell conglomeration in
the tubular lumen. In vivo studies were performed using these
peptides at a calculated systemic concentration approximately ten
times lower than the IC50 established by the in vitro laminin
adhesion assay. Even at this apparently lower concentration (it is
not excluded, however, that the peptides are concentrated in the
tubular lumen), both cyclic RGD peptides significantly reduced
retention of Cr and accelerated Cr recovery in the postischemic
period. Hence, our observations establish that cyclic peptides
containing the RGD sequence ameliorate ischemic ARF. It is
reasonable to suggest that cyclic RGDDFLG and RGDDFV
peptides were effective in inhibiting tubular obstruction by pre-
dominantly preventing cell-cell adhesion, rather than cell-matrix
adhesion. Such an inference is based on four independent lines of
experimental data. First, the peptides were used at concentrations
which were only partially inhibitory for cell-matrix adhesion in the
case of cyclic RGDDFV and non-inhibitory in the case of cyclic
RGDDFLG. Second, comparison of two cyclic RGD peptides
with vastly different inhibitory potencies in the cell-matrix adhe-
sion assay showed that they were equipotent in preventing cell-cell
aggregation in vitro and almost equipotent in ameliorating isch-
emic ARF in vivo. Third, analysis of urine sediments from the
cyclic RGDDFV- and RGDDFLG-treated groups showed dis-
persed cells, in striking contrast to the massive cellular conglom-
erates seen in the urine of control animals. Finally, histological
data in rats treated with the cyclic RGDDFV demonstrated
abolition of tubular obstruction without any detectable effect on
the frequency of necrotic or mitotic cells or the degree of
denudation.
Recently, several strategies to manipulate adhesion molecules
during the course of ischemic injury have been proposed. One
approach explores the therapeutic effects of anti-ICAM-1 and
anti-LFA-1 antibodies. It has been demonstrated that these
antibodies are effective in an acute ischemic myocardial reperfu-
sion model [86, 87]. More recent observations have provided data
on the therapeutic utility of these antibodies in protection against
renal ischemia [88]. Most probably, these effects are confined to
the inhibition of leukocyte migration and/or blood coagulation in
the renal microvascular bed, thus resulting in improved hemody-
namics. In our experiments, thrombotic complications of the
prolonged clamping of the renal artery were negated by virtue of
anticoagulation with heparin performed prior to 45' ischemia.
The approach described in the present work utilizing small,
ultrafilterable and less immunogenic peptides is directed toward
inhibition of tubular obstruction, thus aiming to improve urody-
namics. Future attempts to combine both approaches may lead to
the potentiaton of their effectiveness.
We have recently explored the effect of cyclic RGD peptides in
another model of ARF, specifically, warm ischemia-induced ARF
after orthotopic kidney autotransplantation in pigs [89]. In an
attempt to emulate real harvesting conditions, bilaterally nephrec-
tomized kidneys were exposed to 20 minutes warm ischemia and
stored on ice for 24 hours. Anephric pigs developed severe uremia
by the time of autotransplantation. Harvested kidneys were briefly
perfused with cyclic RGD peptide RGDDFV at the concentration
of 5 I.tM or with the vehicle, and the renal artery was anastomosed
end-to-side with the aorta. Ureters were diverted to the skin to
ease the clearance studies performed for three consecutive days
after autotransplantation. Virtually all animals were anuric on the
day 1 of autotransplantation. Despite the significant variability in
the severity of ARF in individual successful cases, on postopera-
tive days 2 and 3, Cc. was consistently higher on the side of
peptide infusion compared to the internal control infused with the
vehicle only.
Half-life of RGD peptides in the circulation and their
metabolic clearance
Our next goal was to synthesize RGD peptides that can be
successfully tagged with radioactive indicators. Synthetic Gly-Arg-
Gly-Asp-Ser-Pro-Cys (GRGDSPC) peptide containing the C-
terminal cystein was used for the conjugation with 99mTc pertech-
netate (manuscript submitted).
99mTcGRGDSPC (30 j.tCi/0.3 ml) was injected in a tail vein of
normal Sprague-Dawley rats, the animals were sacrificed at
different times postinjection, and the radioactivity accumulated in
different organs was detected with a well-type gamma counter and
expressed on per organ or per gram basis. These procedures were
repeated in rats subjected to the 45 minutes renal ischemia
followed by the contralateral nephrectomy. The clearance of
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blood in both groups of animals was rapid and indistinguishable
between the control and ARF rats (at 10 mm postinjection, the
radioactivity of the blood accounted for 12.91 1.47% and 11.17
2.13% of the injected dose, respectively). In controls, kidneys
accumulated the major portion of the injected radioactivity by 10
minutes postinjection 12.47 0.47% (both kidneys), with the gut
and liver retaining 6.58 0.99% and 5.19 0.49% of the injected
dose, respectively. In ARF group, renal accumulation accounted
for 3.53 1.24% (one kidney), while the gut and liver accumu-
lation accounted for 6.72 0.79% and 3.31 0.44%, respectively.
The other organs (brain, lungs, heart, spleen, and stomach)
contained less than 1% of the injected dose in both groups of
animals. By 180 minutes postinjection, the gut content of 99mTc
amounted to 8.62 0.92% injected dose in control animals, while
the ARF rats showed a significant increase in the amount of the
isotope accumulated in the gut (19.50 2.16% of injected dose,
P < 0.05 vs. timed control). This suggests that in ARF rats, the gut
becomes a significant route for the elimination of 99mTc
GRGDSPC. When the data were expressed per g wet tissue
weight, the kidneys retained the largest portion of the injected
radioactivity at 10 minutes postinjection: 8.42 0.18% of injected
dose/g wet wt in control and 4.42 1.88% of injected dose/g wet
wt in ARF rats, P < 0.05). These data indicate that the renal
excretion of the peptide represents the predominant and specific
route for its elimination.
Given the vastly different renal blood flow and glomerular
filtration rate in control and ARF rats, we next examined the
relative accumulation of v9mTcGRGDSPC in both groups. The
experimental protocol was modified by the double isotope injec-
tion of 1111n-diethylenetriaminepentaacetic acid (DTPA) five
minutes prior to the sacrifice. The results were expressed as the
ratio of the activities 99mTcGRGDSPC/wInDTPA, thus nor-
malizing the amount of the accumulated RGD peptide to the
glomerular filtration rate [90]. At 60 minutes postinjection of
99mTcGRGDSPC the ratio RGD/DTPA in control kidneys
equaled 4.03, while it was more than four times higher in ARF
rats: 17.4. These data indicate that postischemic kidneys retain
99mTc..labeled RGD peptide compared to the normal kidney.
Taking into account our previous findings on the desquamation of
tubular epithelial cells and exposure of the integrin receptors,
normally occupied by the matrix, to the exogenously provided
RGD ligands, the above data are consistent with the specific
binding of the injected 99mTclabeled RGD peptide to these
exposed integrins. Based on these results, it is quite plausible that
the ratio 99mTcRGD:lhInDTPA may serve as a sensitive
diagnostic parameter for detection of tubular obstruction in this
and other pathological conditions.
Potential side effects of RGD peptides
As an integral part of various matrix proteins, RGD-containing
peptides, at least theoretically, should be well tolerated. To date,
no detailed toxicological studies of these peptides have been
published. Based on the available physiological data, the following
potential side effects should be considered.
Platelet dysfunction may represent one possible complication of
systemic administration of RGD peptides. In in vitro experiments
on binding of the biotinylated aIIbI33 integrin to immobilized
fibrinogen, linear GRGDS peptide showed IC50 equal to 10 M,
whereas the cyclic RGDFV peptide was ten times more potent
[81]. In vitro platelet aggregation examined in the presence of
different snake venoms yielded the following information: bar-
bourin, tergeminin and eristicophin inhibited the ADP-induced
aggregation with IC50 equal to 309 nM, 192 nM and 104 nM,
respectively. Clearly, these venom derivatives are much more
potent in inhibiting platelet aggregation than cyclic RGD pep-
tides. Although we have not studied platelet aggregation specifi-
cally, there were no clinical manifestations of coagulopathy in our
in vivo experiments with rats and pigs.
Cell migration may represent another target for RGD peptides.
It has been shown that this process was inhibited in vitro by linear
RGD peptides with half-maximal effect at the concentration of
—10 I.LM [66]. Given the importance of cell migration in restora-
tion of tubular epithelial integrity and barrier function during
postischemic period, when the denuded basement membrane has
to be sealed by migrating neighboring cells remaining in situ, this
potential interference should be seriously considered. In this
respect, the concentration of RGD peptides is of critical impor-
tance. Our experimental use in vivo cyclic RGD peptides at a
concentration of 4 to 5 LM, by far lower than that reported to
inhibit cell migration in other systems (such as inhibition of BSC-1
cell migration at —10 M [66], of human keratinocytes at 100 tM
[91]), not only did not inhibit the recovery from ischemic insult,
but significantly accelerated it. Such an effect would be inconsis-
tent with the possibility of an RGD peptide interfering with the
epithelial wound healing process.
Concluding remarks and future perspectives
This brief review takes stock of the most recent investigations
on the role of integrins in the pathophysiology of ARF. The data
presented above incriminate the redistribution of integrins in
renal tubular epithelial cells in the development of cell desqua-
mation, aggregation and tubular obstruction. Curiously, several
passages in Hippocrates' Aphorisms, though somewhat obscure
today, suggest the amazing prediction of such a mechanism, as in
his observation that "[w]hen small fleshy substances like hairs are
discharged along with thick urine, these substances come from the
kidneys."
We have also summarized compelling evidence, from both in
vitro and in vivo experiments, that RGD peptides moderate the
severity of ARF by inhibiting tubular obstruction. This effect was
observed when the peptides were injected either prior to the
release of the clamp or two hours later, but was blunted when
RGD peptides were injected eight hours later. These findings
suggest that RGD peptides should be further evaluated as poten-
tial therapeutic tools in the management of ARF.
Several targets for future investigations clearly emerge from
this review. The cellular mechanisms leading to the loss of polar
distribution of integrins in stressed renal tubular epithelial cells,
the precise identity of integrins participating in this process, as
well as the modes of cell-cell interaction leading to the obstruction
of tubular lumen remain to be elucidated. Any potential side
effects of RGD peptides should be thoroughly investigated.
Clearly, broad toxicological studies of RGD peptides ought to be
performed before any attempts to introduce them into the
management of selected forms of ARF are undertaken.
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